GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Nanogen Gains Access to Schizophrenia Markers

  • Nanogen acquired rights to genetic markers related to schizophrenia and responses to antipsychotic therapies from the Co-operative Research Centre for Diagnostics and Queensland University of Technology in Australia.

    Nanogen plans to utilize the markers to create diagnostic tests. Some of these markers may also help predict adverse drug reactions and therefore guide therapeutic decision-making.

    "Due to its complexity—schizophrenia, like many mental disorders, is believed to be caused by mutations in multiple genes— development of effective diagnostics and treatments is likely to require multiplexed analytic methods capable of examining multiple genes simultaneously," remarks David Ludvigson, Nanogen's president and COO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »